** Shares of Nvidia-backed AI drug developer Recursion Pharmaceuticals RXRX.O fall 13% to $6.67 premarket
** The company posts Q4 revenue of $4.5 million, missing analysts' estimate of $19 million, according to data compiled by LSEG
** Reports Q4 net loss of 53 cents per share versus a loss estimate of 43 cents per share
** Recursion wants to be the Amazon Prime of pharma by adopting a subscription model for selling its pipeline of medicines, Bloomberg reports
** The company files for stock offering of up to $500 million - filing
** It has ~390 mln outstanding shares, with a market capitalization of $3 bln, according to data compiled by LSEG
** RXRX has fallen ~51% in the last 12 months
(Reporting by Siddhi Mahatole)
((Siddhi.mahatole@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。